@article{oai:nagasaki-u.repo.nii.ac.jp:00005890,
 author = {Shimada, Midori and Fukuda, Minoru and Onn, Yumi and Abe, Noriko and Irie, Junji and Kitazaki, Takeshi and Hashiguchi, Kohji and Fukuda, Masaaki and Nakamura, Yoichi and Suyama, Naofumi and Ashizawa, Kazuto and Kohno, Shigeru},
 issue = {2},
 journal = {Acta medica Nagasakiensia},
 month = {Dec},
 note = {Introduction
　Gefitinib is a molecularly targeted drug for oral administration, a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). It is effective for patients with lung cancer who have EGFR mutation and enables long-term survival of patients with advanced disease.
Case presentation
　An 84-year-old Asian female with lung cancer (adenocarcinoma, cT4N3M1b stage IV PUL BRA OSS ADR) was treated by gefitinib for two years. The primary tumor was markedly reduced, and bone metastasis had almost disappeared. However, the patient became unconsciousness with general edema and died two days after falling unconsciousness. In the autopsy, it was diagnosed as infectious cerebral thromboembolism due to infectious endocarditis. The cause of death was cardiac tamponade.
Conclusions
　While long-term survival can be expected in patients with advanced lung cancer by molecular-targeted agents, cautious management is warranted for complications, the same as for the primary disease., Acta medica Nagasakiensia, 59(2), pp.67-71; 2014},
 pages = {67--71},
 title = {Infectious cerebral thromboembolism in a patient with lung cancer during long-term administration of gefitinib: a case report},
 volume = {59},
 year = {2014}
}